myTAIHEART Test Provides Evidence for Injury from Biopsy of Heart Transplant Recipients

MILWAUKEE, Wis.–(BUSINESS WIRE)–TAI Diagnostics, Inc., focused on developing innovative diagnostic tests for monitoring the health of transplanted organs, today announced the publication, “Effect of endomyocardial biopsy on levels of donor-specific cell-free DNA” in the October, 2019 issue of The Journal of Heart and Lung Transplantation. The clinical study presented in the paper was conducted jointly by Steven Zangwill, MD, Karl Stamm, PhD, Mats Hidestrand, PhD, Aoy Tomita-Mitchell, PhD and Michael Mitchell, MD.

Invenra Announces Expansion of Collaboration with Exelixis

MADISON, WI, USA, Oct 31, 2019 – Invenra Inc. announced that it has expanded its collaboration with Exelixis, Inc. (Nasdaq: EXEL). Exelixis and Invenra had entered into a collaboration on May 2nd, 2018 to discover and develop multispecific antibodies through the use...

Curate is now live in all 50 states

I’m thrilled to announce that Curate has expanded to cover all 50 U.S. states. Expanding our geographic footprint has been a huge push over the last few months, and our hard work has now paved the way for us to welcome hundreds of new customers across the country. In...

Shine Medical Technologies debuts therapeutics division

Medical isotopes maker Shine Medical Technologies last week created a division to make therapeutic products, saying it plans to first focus on a cancer treatment. The Janesville, Wis.-based company said its Shine Therapeutics business will begin with the development...